PMID- 31118893
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 10
DP  - 2019
TI  - Safety and Efficacy of Anti-PD-1 Monoclonal Antibodies in Patients With Relapsed 
      or Refractory Lymphoma: A Meta-Analysis of Prospective Clinic Trails.
PG  - 387
LID - 10.3389/fphar.2019.00387 [doi]
LID - 387
AB  - Background: Immune checkpoint inhibition therapy with monoclonal antibody against 
      programmed cell death protein 1 (PD-1), including nivolumab and pembrolizumab, 
      has demonstrated powerful clinical efficacy in the treatment of advanced cancers. 
      However, there is no evidence-based systematic review on the safety and efficacy 
      of anti-PD-1 antibody in treating lymphoma. Methods: To evaluate the safety and 
      efficacy of nivolumab/pembrolizumab, we analyzed clinical trials from PUBMED, 
      EMBASE, and The Cochrane Library. For safety analysis, the incidence and 
      exhibition of any grade and grade >/=3 adverse events (AEs) were evaluated. Overall 
      response rate (ORR), 6-month progression-free survival (PFS) and 6-month overall 
      survival (OS) were calculated for efficacy analysis. Results: Overall ten studies 
      and 718 patients (114 non-Hodgkin lymphomas, 604 Hodgkin lymphomas) were 
      enrolled, including 4 phase I studies and 6 phase II studies. The pooled 
      incidences of any grade and grade >/=3 adverse events (AEs) were 74 and 24%, 
      respectively. Drug-related deaths occurred in two patients. The most common any 
      grade AEs were fatigue (14.91%), rash (14.8%), hypothyroidism (13.77%), platelet 
      count decreased (13.54%), pyrexia (13%). The most common grade >/=3 AEs were 
      neutropenia (4.79%), pneumonitis (3.58%), rash (3.38%), and leukopenia (3.31%). 
      Fatigue (p = 0.0072) and rash (p = 0.0078) in any grade AEs were less observed in 
      patients treated with pembrolizumab than nivolumab. The pooled ORR, PFS rate and 
      OS rate were 58, 73, and 96%, respectively. The ORR in patients with Hodgkin 
      lymphomas (HL) was higher than patients with non-Hodgkin lymphomas (NHL) (69.08 
      vs. 30.77%, p < 0.0001). However, there was no significant difference of efficacy 
      between nivolumab and pembrolizumab. Conclusions: Nivolumab and pembrolizumab 
      have promising outcomes with tolerable AEs and drug-related deaths in patients 
      with relapsed or refractory lymphoma. Pembrolizumab caused less any grade AEs 
      like fatigue and rash than nivolumab. Patients with HL got better response than 
      NHL.
FAU - Zhou, Hui
AU  - Zhou H
AD  - Department of Hematology and Research Laboratory of Hematology, West China 
      Hospital, Sichuan University, Chengdu, China.
FAU - Fu, Xiaoyan
AU  - Fu X
AD  - Department of Hematology and Research Laboratory of Hematology, West China 
      Hospital, Sichuan University, Chengdu, China.
FAU - Li, Qian
AU  - Li Q
AD  - Department of Hematology and Research Laboratory of Hematology, West China 
      Hospital, Sichuan University, Chengdu, China.
FAU - Niu, Ting
AU  - Niu T
AD  - Department of Hematology and Research Laboratory of Hematology, West China 
      Hospital, Sichuan University, Chengdu, China.
LA  - eng
PT  - Systematic Review
DEP - 20190501
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC6504777
OTO - NOTNLM
OT  - anti-PD-1 monoclonal antibodies
OT  - efficacy
OT  - nivolumab
OT  - pembrolizumab
OT  - relapsed or refractory lymphoma
OT  - safety
EDAT- 2019/05/24 06:00
MHDA- 2019/05/24 06:01
PMCR- 2019/05/01
CRDT- 2019/05/24 06:00
PHST- 2019/01/01 00:00 [received]
PHST- 2019/03/28 00:00 [accepted]
PHST- 2019/05/24 06:00 [entrez]
PHST- 2019/05/24 06:00 [pubmed]
PHST- 2019/05/24 06:01 [medline]
PHST- 2019/05/01 00:00 [pmc-release]
AID - 10.3389/fphar.2019.00387 [doi]
PST - epublish
SO  - Front Pharmacol. 2019 May 1;10:387. doi: 10.3389/fphar.2019.00387. eCollection 
      2019.